EA201000238A1 - Антигенсвязывающие белки для il-18 рецептора и их применение - Google Patents

Антигенсвязывающие белки для il-18 рецептора и их применение

Info

Publication number
EA201000238A1
EA201000238A1 EA201000238A EA201000238A EA201000238A1 EA 201000238 A1 EA201000238 A1 EA 201000238A1 EA 201000238 A EA201000238 A EA 201000238A EA 201000238 A EA201000238 A EA 201000238A EA 201000238 A1 EA201000238 A1 EA 201000238A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
binding proteins
antigen
application
antigen binding
Prior art date
Application number
EA201000238A
Other languages
English (en)
Other versions
EA016783B1 (ru
Inventor
Дирк Е. Смит
Джон Е. Симз
Джеффри Т. Макгрю
Марек З. Кубин
Дункан Кочрейн
Луиз Конрой
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA201000238A1 publication Critical patent/EA201000238A1/ru
Publication of EA016783B1 publication Critical patent/EA016783B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Изобретение включает антигенсвязывающие белки для связывания IL-18 рецептора и кодирующие их полинуклеотиды. Также включаются векторы экспрессии и содержащие их клетки-хозяева для продуцирования антигенсвязывающих белков. Кроме того, включаются композиции и способы диагностики и лечения заболеваний, опосредуемых IL-18 рецептором.
EA201000238A 2007-07-24 2008-07-24 Антигенсвязывающие белки для il-18 рецептора и их применение EA016783B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95169107P 2007-07-24 2007-07-24
US95169207P 2007-07-24 2007-07-24
US7314208P 2008-06-17 2008-06-17
PCT/US2008/071047 WO2009015284A2 (en) 2007-07-24 2008-07-24 Il-18 receptor antigen binding proteins

Publications (2)

Publication Number Publication Date
EA201000238A1 true EA201000238A1 (ru) 2010-08-30
EA016783B1 EA016783B1 (ru) 2012-07-30

Family

ID=40282148

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000238A EA016783B1 (ru) 2007-07-24 2008-07-24 Антигенсвязывающие белки для il-18 рецептора и их применение

Country Status (17)

Country Link
US (3) US8257707B2 (ru)
EP (1) EP2178917A4 (ru)
JP (2) JP2010534478A (ru)
KR (1) KR20100049535A (ru)
CN (1) CN101835489B (ru)
AR (1) AR067666A1 (ru)
AU (1) AU2008279127B2 (ru)
BR (1) BRPI0813016A2 (ru)
CA (1) CA2693503A1 (ru)
CL (1) CL2008002153A1 (ru)
EA (1) EA016783B1 (ru)
IL (1) IL202833A0 (ru)
PE (1) PE20090518A1 (ru)
SG (1) SG183070A1 (ru)
TW (1) TWI436778B (ru)
WO (1) WO2009015284A2 (ru)
ZA (1) ZA201001140B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CA2805054A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
DK2857420T3 (da) 2012-05-30 2020-11-23 Chugai Pharmaceutical Co Ltd Målvævsspecifikt antigenbindende molekyle
US8821242B2 (en) 2012-07-25 2014-09-02 Lumos Labs, Inc. Systems and methods for enhancing cognition
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
KR102085179B1 (ko) * 2013-05-07 2020-04-16 삼성전자주식회사 디바이스의 위치에 기초한 콘텐트 제공 시스템 및 방법
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
SG11201604495PA (en) 2013-12-04 2016-07-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
EP3182916A4 (en) 2014-08-20 2018-03-07 Covidien LP Systems and methods for spherical ablations
KR20160047889A (ko) * 2014-10-23 2016-05-03 삼성전자주식회사 전자 장치 및 피공유자 추천 서비스 운용 방법
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
MA52186A (fr) 2018-03-26 2021-02-17 Amgen Inc Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
WO2019242655A1 (en) * 2018-06-19 2019-12-26 Shanghaitech University Human antibodies to human interleukin 18 receptor alpha and beta
CA3060547A1 (en) * 2018-07-13 2020-01-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2021062372A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4229080A1 (en) 2020-10-15 2023-08-23 Amgen Inc. Relative unpaired glycans in antibody production methods
CN114736291B (zh) * 2021-01-07 2023-08-11 中国科学院微生物研究所 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
CN117177999A (zh) * 2022-01-14 2023-12-05 和径医药科技（上海）有限公司 一种靶向IL-18Rβ的抗体及其应用
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
AU737592B2 (en) * 1998-01-23 2001-08-23 Immunex Corporation Il-18 receptors
DE69926480T2 (de) * 1998-01-23 2006-04-13 Immunex Corp., Thousand Oaks Acpl dna und polypeptide
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
IL131047A0 (en) 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
TWI373343B (en) 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
PT2275449T (pt) * 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2002211658A1 (en) 2000-10-13 2002-04-22 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
EA009125B1 (ru) 2001-05-16 2007-10-26 Йеда Рисерч Энд Дивелопмент Ко., Лтд. Применение ингибиторов il-18 для лечения и/или предупреждения заболеваний, характерных для синдрома системной воспалительной реакции
AU2002365269A1 (en) 2001-10-26 2003-07-24 Centocor, Inc. Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
CA2467738A1 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
US20070025992A1 (en) * 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US7887802B2 (en) * 2004-07-16 2011-02-15 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist

Also Published As

Publication number Publication date
AR067666A1 (es) 2009-10-21
PE20090518A1 (es) 2009-04-25
JP2010534478A (ja) 2010-11-11
US8257707B2 (en) 2012-09-04
BRPI0813016A2 (pt) 2015-12-15
CA2693503A1 (en) 2009-01-29
US20110014201A1 (en) 2011-01-20
AU2008279127A1 (en) 2009-01-29
EP2178917A2 (en) 2010-04-28
EA016783B1 (ru) 2012-07-30
CL2008002153A1 (es) 2009-06-05
CN101835489B (zh) 2013-10-16
TW200927167A (en) 2009-07-01
JP2015015957A (ja) 2015-01-29
SG183070A1 (en) 2012-08-30
US20130034569A1 (en) 2013-02-07
EP2178917A4 (en) 2012-03-28
KR20100049535A (ko) 2010-05-12
TWI436778B (zh) 2014-05-11
IL202833A0 (en) 2011-08-01
ZA201001140B (en) 2011-03-30
US8540993B2 (en) 2013-09-24
WO2009015284A3 (en) 2009-10-01
CN101835489A (zh) 2010-09-15
WO2009015284A2 (en) 2009-01-29
WO2009015284A8 (en) 2009-07-02
AU2008279127B2 (en) 2014-03-27
US20140093915A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201490677A1 (ru) Связывающие антиген cd27l белки
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
EA201890169A1 (ru) Тау-связывающие антитела
EA201492149A1 (ru) St2-антигенсвязывающие белки
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA201791577A1 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
EA201492101A1 (ru) Антитела против fcrn
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
PH12013502205A1 (en) Antibodies to il-6 and their uses
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
EA201101242A1 (ru) Полностью человеческие антитела, специфические для cadm1
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
EA201690503A1 (ru) Антитела
EA201300470A1 (ru) Антитела
JO2991B1 (ar) بروتينات رابطة لمولد ضد المستقبل ايه للانترليوكين 17
WO2014062245A3 (en) Antigen binding proteins that bind dll-4

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU